Pure Global
NCT00320398

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery
GlaxoSmithKline·Phase 3·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Thrombosis, Venous
Drug/Device/Intervention
Fondaparinux
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
GlaxoSmithKline
Timeline & enrollment
Phase
Phase 3
Start date
Jan 30, 2006
End date
Jul 18, 2006
Enrollment
114 participants
Primary outcome

Percentage of Participants With Venous Thromboembolism (VTE) During Efficacy Period,Percentage of Participants With Major Bleeding

Summary

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).

ICD-10 classifications
Other venous embolism and thrombosisEmbolism and thrombosis of unspecified veinEmbolism and thrombosis of other specified veinsPerianal venous thrombosisArterial embolism and thrombosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00320398
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00320398 through Pure Global AI's free database. This Phase 3 trial is sponsored by GlaxoSmithKline and is currently Completed. The study focuses on Thrombosis, Venous. Target enrollment is 114 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.